Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Atherosclerotic Cardiovascular Disease: later-stage trial registry
6 of 22 indexed Atherosclerotic Cardiovascular Disease trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #756 of 28,707 conditions by registered trial count.
22 US clinical trials · 6 currently recruiting · #756 of 28,707 conditions by registered trial count
Atherosclerotic Cardiovascular Disease: 22 US clinical trials tracked, 6 recruiting.
Atherosclerotic Cardiovascular Disease is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Amgen, running 3 of these trials.
Enrollment posture brief
Registry condition atherosclerotic-cardiovascular-disease
OPEN 6 | RECR 27% | LATE 10 | EARLY 3 | RANK #756 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Behavior and Behavior Mechanisms (27% recruiting · 11 trials)
Atherosclerotic Cardiovascular Disease lists 6 open slots (27% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Atherosclerotic Cardiovascular Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Atherosclerotic Cardiovascular Disease is recruiting below its size-band peers.
6 of 22 indexed trials (27.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Atherosclerotic Cardiovascular Disease trials is spread across many organizations.
Amgen accounts for 3 of 22 trials (13.6%). 16 distinct sponsors appear on at least one study for this condition label.
-
Typical Atherosclerotic Cardiovascular Disease enrolment sits around 599 participants.
Median target enrolment is 599 among the 22 trials that report a genuine target (sentinel values excluded). 4 of those (18.2%) plan for fewer than 100 participants.
-
Atherosclerotic Cardiovascular Disease research is mostly interventional.
20 interventional and 2 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
22 total, page 1 of 1
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
NCT07037433
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
CSL Behring
NCT05485961
The Prevent Coronary Artery Disease Trial
Icahn School of Medicine at Mount Sinai
NCT06494501
Pelacarsen Roll-over Extension Program
Novartis Pharmaceuticals
NCT06875973
A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients
Intermountain Health Care
NCT06571162
Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure
University of Alabama at Birmingham
NCT06962488
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
Novartis Pharmaceuticals
NCT05030428
A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease
University of Oxford
NCT03705234
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NewAmsterdam Pharma
NCT05202509
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
Amgen
NCT05581303
VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
Duke University
NCT06249165
The Young Heart Study
Northwell Health
NCT04462159
Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)
Brigham and Women's Hospital
NCT07203677
A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)
Amgen
NCT05378529
Behavioral Economic Approaches to Increase Physical Activity Among Patients With Elevated Risk for Cardiovascular Disease
University of Pennsylvania
NCT03911141
An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol
Novartis Pharmaceuticals
NCT03060577
Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity
University of Florida
NCT03096288
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
AstraZeneca
NCT06692764
Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study
Icahn School of Medicine at Mount Sinai
NCT02576067
A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia
Novartis
NCT06507852
Recipe for Heart Health
University of Florida
NCT04828447
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis
National Heart, Lung, and Blood Institute (NHLBI)
NCT04271735
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 8 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Atherosclerotic Cardiovascular Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Atherosclerotic Cardiovascular Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Atherosclerotic Cardiovascular Disease page
22 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Atherosclerotic Cardiovascular Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amgen sponsors the most Atherosclerotic Cardiovascular Disease trials on record, review their full trial history before evaluating a specific study. See Amgen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Atherosclerotic Cardiovascular Disease condition card totals 22 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.